Brand-name drug
Mounjaro price, strengths & recalls
Brand of tirzepatide (generic)
Pharmacies pay $1,077.39 for 2 mL of Mounjaro 10 mg/mL, 0.5 mL auto-injector this week, and from $1,077.14 to $1,077.52 across its 6 priced strengths and forms. It has 28 recalls on record, none ongoing. Its official label last changed on September 2, 2026.
Brand- Fair cash price
- $1,249.50
- Strengths
- 6
- Makers
- 1
- Updated
- Nov 11
Mounjaro price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 5 mg/mL, 0.5 mL auto-injector Brand | $538.75 | $1,077.50 / 2 mL |
| 10 mg/mL, 0.5 mL auto-injector Brand | $538.70 | $1,077.39 / 2 mL |
| 15 mg/mL, 0.5 mL auto-injector Brand | $538.74 | $1,077.49 / 2 mL |
| 20 mg/mL, 0.5 mL auto-injector Brand | $538.76 | $1,077.52 / 2 mL |
| 25 mg/mL, 0.5 mL auto-injector Brand | $538.59 | $1,077.17 / 2 mL |
| 30 mg/mL, 0.5 mL auto-injector Brand | $538.57 | $1,077.14 / 2 mL |
Mounjaro vs generic tirzepatide
There is no generic version of Mounjaro on the market yet. Its last listed patent or exclusivity runs to December 30, 2041 - generics often follow, though court cases and settlements can move the date either way.
GenericTirzepatide pricesSupply status: shortages & recalls
Recalls
Showing the 6 most relevant of 28 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Mounjaro
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022
WARNING: RISK OF THYROID C-CELL TUMORS
In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
[see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
[see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO
[see Contraindications (4) and Warnings and Precautions (5.1)].
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).
Recent major changes (as listed on the label)
Indications and Usage
| |
| Pediatric Patients 10 Years of Age and Older (1)
| 12/2025
|
| Major Adverse Cardiovascular Events (1)
| 08/2026
|
Dosage and Administration
| |
| Recommended Dosage (2.1)
| 08/2026
|
| Important Administration Instructions (2.2)
| 01/2026
|
Warnings and Precautions
| |
| Severe Gastrointestinal Adverse Reactions (5.6)
| 12/2025
|
| Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy (5.7)
| 08/2026
|
| Never Share a MOUNJARO KwikPen Between Patients (5.10)
| 01/2026
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA215866 · Eli Lilly And Co
- First approved
- May 13, 2022 (4 years ago)
- Latest approved change
- August 27, 2026
- Approved label
- PDF, Sep 1, 2026
- Generic makers
- None on the market
- Last patent listed
- December 30, 2041
- Exclusivity ends
- December 19, 2028
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Mounjaro questions
How much does mounjaro cost without insurance?
Pharmacies pay about $1,077.39 for 2 mL of mounjaro 10 mg/mL, 0.5 mL auto-injector ($538.70 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $1,249.50. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Mounjaro?
Yes: tirzepatide. Compare tirzepatide prices.
Is mounjaro in shortage?
No shortage is reported for mounjaro right now. We check the national shortage list every day.
Has mounjaro been recalled?
28 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the mounjaro label last change?
The official label was last updated on September 2, 2026 (version 40). See what changed.
Talk about mounjaro
No comments yet. Questions, tips, what worked for you - start the conversation.